As of 2025-09-18, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 477.44 mil USD. SAGE's TTM EBITDA according to its financial statements is -294.68 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 13.6x | 13.0x |
| Forward P/E multiples | 19.2x - 43.4x | 31.3x |
| Fair Price | (89.05) - (62.76) | (102.89) |
| Upside | -1125.9% - -823.1% | -1285.4% |
| Date | EV/EBITDA |
| 2025-07-30 | -1.62 |
| 2025-07-29 | -1.62 |
| 2025-07-28 | -1.64 |
| 2025-07-25 | -1.65 |
| 2025-07-24 | -1.64 |
| 2025-07-23 | -1.64 |
| 2025-07-22 | -1.64 |
| 2025-07-21 | -1.68 |
| 2025-07-18 | -1.71 |
| 2025-07-17 | -1.72 |
| 2025-07-16 | -1.72 |
| 2025-07-15 | -1.72 |
| 2025-07-14 | -1.72 |
| 2025-07-11 | -1.75 |
| 2025-07-10 | -1.73 |
| 2025-07-09 | -1.73 |
| 2025-07-08 | -1.72 |
| 2025-07-07 | -1.72 |
| 2025-07-03 | -1.73 |
| 2025-07-02 | -1.71 |
| 2025-07-01 | -1.71 |
| 2025-06-30 | -1.71 |
| 2025-06-27 | -1.72 |
| 2025-06-26 | -1.75 |
| 2025-06-25 | -1.74 |
| 2025-06-24 | -1.74 |
| 2025-06-23 | -1.75 |
| 2025-06-20 | -1.75 |